ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia

被引：6
|
作者：
De Propris, Maria Stefania [1 ]
Intoppa, Stefania [1 ]
Milani, Maria Laura [1 ]
Mariglia, Paola [1 ]
Nardacci, Maria Grazia [1 ]
Peragine, Nadia [1 ]
Foa, Robin [1 ]
Guarini, Anna [1 ]
机构：
[1] Sapienza Univ, Dept Translat & Precis Med, Hematol, Rome, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 190卷 / 06期
关键词：
CLL; ROR1; MRD; progression disease; haematogones; RECEPTOR TYROSINE KINASE;
D O I：
10.1111/bjh.16910
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e346 / e349
页数：4
相关论文
共 50 条
  • [1] Minimal residual disease in chronic lymphocytic leukaemia
    Garcia Vela, Jose Antonio
    Garcia Marco, Jose Antonio
    [J]. MEDICINA CLINICA, 2018, 150 (04): : 144 - 149
  • [2] Minimal residual disease assessment in chronic lymphocytic leukaemia
    Sayala, Hazem A.
    Rawstron, Andy C.
    Hillmen, Peter
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (03) : 499 - 512
  • [3] Combined ROR1 and CD160 Detection For Improved Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia (CLL)
    Farren, Timothy W.
    Liu, Fengting
    Macey, Marion G.
    Kipps, Thomas J.
    Warner, Noel
    Agrawal, Samir G.
    [J]. BLOOD, 2013, 122 (21)
  • [4] Minimal residual disease in chronic lymphocytic leukaemia:: is it ready for primetime?
    Nabhan, Chadi
    Coutre, Steven
    Hillmen, Peter
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (03) : 379 - 392
  • [5] Does CD5 have an effect on the expression of ROR1 in chronic lymphocytic leukaemia?
    Alsulami, H. A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 72 - 72
  • [6] ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL)
    Patz, Michaela
    Pentok, Barbara
    Cremer, Kathrin
    Linnartz, Stefanie
    Lilienweiss, Esther
    Kleinert, Fanni
    Hallek, Michael
    Kreuzer, Karl-Anton
    [J]. BLOOD, 2016, 128 (22)
  • [7] Novel humanised ROR1 Bispecific T-cell Engager for the treatment of chronic lymphocytic leukaemia
    Gohil, Satyen
    Nathwani, Amit
    Harrasser, Micaela
    Paredes, Solange
    Della Peruta, Marco
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 230 - 231
  • [8] Minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL) via an 8 color flow cytometry panel comprising the signature gene ROR1
    Patz, Michaela
    Pentok, Barbara
    Cremer, Kathrin
    Linnartz, Stefanie
    Lilienweiss, Esther
    Kleinert, Fanni
    Hallek, Michael
    Kreuzer, Karl-Anton
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 93 - 94
  • [9] Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay
    Farren, Timothy W.
    Sadanand, Kaushik S.
    Agrawal, Samir G.
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?
    Fink, Anna M.
    [J]. LANCET HAEMATOLOGY, 2019, 6 (09): : E441 - E442
12345